CO6382130A2 - Nuevos compuestos de imidazolidina como moduladores del receptor de androdenos - Google Patents

Nuevos compuestos de imidazolidina como moduladores del receptor de androdenos

Info

Publication number
CO6382130A2
CO6382130A2 CO11043783A CO11043783A CO6382130A2 CO 6382130 A2 CO6382130 A2 CO 6382130A2 CO 11043783 A CO11043783 A CO 11043783A CO 11043783 A CO11043783 A CO 11043783A CO 6382130 A2 CO6382130 A2 CO 6382130A2
Authority
CO
Colombia
Prior art keywords
androden
imidazolidine compounds
receiver modulators
new
compounds
Prior art date
Application number
CO11043783A
Other languages
English (en)
Inventor
Francois Nique
Catherine Jagerschmidt
Roland Blanque
Jean Michel Lefrancois
Christophe Peixoto
Pierre Deprez
Nicolas Triballeau
Piet Tom Bert Paul Wigerinck
Florence Sylvie Namour
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of CO6382130A2 publication Critical patent/CO6382130A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen nuevos compuestos representados por la siguiente Fórmula:en donde X, R1, R2a, R2b, R2c, R3a R3b, R4a, R4b, R4c y m1 son como se describe en la presente. Los compuestos se pueden preparar como composiciones farmacéuticas, y se pueden usar para la prevención y el tratamiento de una variedad de afecciones en mamíferos, incluido el ser humano, que incluyen, a modo de ejemplos no limitativos, caquexia, osteoporosis, sarcopenia, disminución de la libido y/o disfunción sexual.
CO11043783A 2008-09-11 2011-04-08 Nuevos compuestos de imidazolidina como moduladores del receptor de androdenos CO6382130A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19191808P 2008-09-11 2008-09-11
GB0900333.6A GB2463514C (en) 2008-09-11 2009-01-09 Imidazolidine compounds and uses therefor

Publications (1)

Publication Number Publication Date
CO6382130A2 true CO6382130A2 (es) 2012-02-15

Family

ID=40379370

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11043783A CO6382130A2 (es) 2008-09-11 2011-04-08 Nuevos compuestos de imidazolidina como moduladores del receptor de androdenos

Country Status (20)

Country Link
US (2) US7968581B2 (es)
EP (1) EP2344460B1 (es)
JP (1) JP5595402B2 (es)
KR (1) KR101705157B1 (es)
CN (1) CN102149687B (es)
AR (1) AR073282A1 (es)
AU (1) AU2009290849B2 (es)
BR (1) BRPI0919290A2 (es)
CA (1) CA2736364C (es)
CO (1) CO6382130A2 (es)
ES (1) ES2552684T3 (es)
GB (1) GB2463514C (es)
HK (1) HK1141015A1 (es)
IL (1) IL211277A (es)
MX (1) MX2011002374A (es)
NZ (1) NZ591374A (es)
RU (1) RU2488584C2 (es)
TW (1) TWI449698B (es)
WO (1) WO2010029119A1 (es)
ZA (1) ZA201101707B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168667B2 (en) * 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
BR112013023028B1 (pt) 2011-03-10 2021-09-21 Suzhou Kintor Pharmaceuticals, Inc Composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e formulação farmacêutica tópica
GB201311107D0 (en) * 2013-06-21 2013-08-07 Univ Edinburgh Bioorthogonal methods and compounds
EP3021841B1 (en) * 2013-07-18 2022-11-16 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
CN105979943A (zh) * 2013-10-25 2016-09-28 厄恩斯特.D.布什 肌营养不良的治疗方法
CN106573921B (zh) * 2013-12-31 2019-05-07 博福-益普生（天津）制药有限公司 咪唑烷-2,4-二酮衍生物
US11662606B2 (en) * 2017-12-06 2023-05-30 Eyebright Medical Technology (Beijing) Co., Ltd. Orthokeratology lens and method for making orthokeratology lenses
EP3773537B1 (en) 2018-04-19 2022-03-23 Tvardi Therapeutics, Inc. Stat3 inhibitors
US11026905B2 (en) 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
EP4093377A1 (en) 2020-01-24 2022-11-30 Tvardi Therapeutics, Inc. Therapeutic compounds, formulations, and uses thereof
CN113024513A (zh) * 2021-03-22 2021-06-25 中国药科大学 新型雄激素受体降解剂、制备方法和医药用途
CN113801064A (zh) * 2021-09-26 2021-12-17 甘肃省化工研究院有限责任公司 一种[3+2]环加成反应构建苯基乙内酰脲的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5136332B1 (es) * 1970-12-09 1976-10-07
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
DE2855770A1 (de) 1978-12-22 1980-07-10 Bayer Ag Hydantoine
US4753957A (en) 1981-09-28 1988-06-28 Rohm And Haas Company Substituted 2,4-imidazolidinediones and fungicidal compositions
EP0091596B1 (de) 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
FR2619381B1 (fr) * 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
JP2566792B2 (ja) 1987-09-30 1996-12-25 株式会社資生堂 発毛、養毛促進剤
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
US4992443A (en) 1990-03-12 1991-02-12 William Chelen Method of treating motion sickness
US5346913A (en) 1992-05-26 1994-09-13 Rohm And Haas Company N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
JP3137430B2 (ja) 1992-06-10 2001-02-19 鐘淵化学工業株式会社 ５，５−二置換ヒダントインの製造法
US6846525B2 (en) 1993-03-19 2005-01-25 Xerox Corporation Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
CA2188427C (en) 1994-04-29 2000-06-27 Robert A. Volkmann Neurotransmitter release enhancers
EP0760239A3 (en) 1995-09-01 1999-04-14 Pfizer Inc. Therapeutic agents for use in cancer therapy
FR2741342B1 (fr) * 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
BR9811260A (pt) 1997-03-03 2000-08-08 Boehringer Ingelheim Pharma Pequenas moléculas úteis no tratamento de doença inflamatória
US6355664B1 (en) 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
UA57081C2 (uk) 1997-06-16 2003-06-16 Пфайзер Продактс Інк. Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
EP0945441A3 (de) 1998-03-27 2002-07-17 Degussa AG Verfahren zur Herstellung von cyclischen 4-Oxoamidinen
HUP0302002A3 (en) 2000-05-11 2007-02-28 Consejo Superior Investigacion Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them
US6846643B2 (en) 2000-08-14 2005-01-25 Boehringer Ingelheim Pharmaceuticals, Inc. Methods and molecules useful for identifying molecules that bind LFA-1 and for determining receptor occupancy
JP5031568B2 (ja) * 2004-09-10 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドロゲン受容体モジュレーター（ｓａｒｍｓ）としての新規なイミダゾリジン−２−オン誘導体
CN101304976A (zh) 2005-10-11 2008-11-12 因特蒙公司 病毒复制抑制剂
GB0610765D0 (en) * 2006-05-31 2006-07-12 Proskelia Sas Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such

Also Published As

Publication number Publication date
RU2488584C2 (ru) 2013-07-27
EP2344460B1 (en) 2015-08-12
JP5595402B2 (ja) 2014-09-24
GB0900333D0 (en) 2009-02-11
KR20110067029A (ko) 2011-06-20
CN102149687A (zh) 2011-08-10
CA2736364C (en) 2018-06-26
GB2463514B (en) 2010-07-28
WO2010029119A1 (en) 2010-03-18
GB2463514A (en) 2010-03-17
AU2009290849A1 (en) 2010-03-18
BRPI0919290A2 (pt) 2019-04-30
US20100113547A1 (en) 2010-05-06
EP2344460A1 (en) 2011-07-20
CN102149687B (zh) 2014-08-13
CA2736364A1 (en) 2010-03-18
TWI449698B (zh) 2014-08-21
NZ591374A (en) 2012-07-27
ES2552684T3 (es) 2015-12-01
MX2011002374A (es) 2011-04-11
US20120178718A1 (en) 2012-07-12
ZA201101707B (en) 2012-01-25
IL211277A (en) 2014-12-31
JP2012524708A (ja) 2012-10-18
US8383608B2 (en) 2013-02-26
KR101705157B1 (ko) 2017-02-09
TW201016671A (en) 2010-05-01
US7968581B2 (en) 2011-06-28
GB2463514C (en) 2018-09-26
AU2009290849B2 (en) 2015-04-02
HK1141015A1 (en) 2010-10-29
RU2011113749A (ru) 2012-10-20
AR073282A1 (es) 2010-10-28
IL211277A0 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
CO6382130A2 (es) Nuevos compuestos de imidazolidina como moduladores del receptor de androdenos
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
NI201200013A (es) Composición de insulina de acción prolongada
NI201100162A (es) Derivados de indol como antagonistas del receptor crth2
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
ECSP14013312A (es) Composiciones para el tratamiento de vhc
HN2012001321A (es) Analogo peptidico de oxintomodulina
NI201100160A (es) Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3
GT201200144A (es) Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina
CR11751A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta3
AR077450A1 (es) Procedimiento para mejorar el crecimiento de plantulas y/o la emergencia temprana de cosechas
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CU20100035A7 (es) Derivados de ciclopropilamida como moduladores h3
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
ECSP17025302A (es) N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b
CR20110029A (es) Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina
ECSP109923A (es) Bromhidrato de bupropion y aplicaciones terapéuticas
CR20130530A (es) Derivados glucósidos y sus usos para el tratamiento de la diabetes
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CL2008002767A1 (es) Compuestos derivados de heterociclico triciclico; composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por serotonina tal como obesidad, esquizofrenia y disfuncion cognitiva.
CO6290768A2 (es) Tiazolil-dihidro-indazoles
CO6460762A2 (es) 5-alquinil-piridinas

Legal Events

Date Code Title Description
FC Application refused